IBM's Quantum Gains Grab Headlines, But the Software Engine Still Drives the Stock
Published on 09/02/2026 at 13:11 | Editorial boerse-global.de
The narrative around IBM has quietly shifted. Where the company once leaned on the physics of quantum processors to tell its future story, it now points to the factory floor. Speaking before the chip industry, IBM argued that the real bottleneck in quantum computing is no longer the science — it's the manufacturing. The specifics of that pitch were largely paywalled, but the positioning is unmistakable: IBM believes it holds the technological edge and wants the conversation to move to industrial scale.
That claim is backed by a string of recent research wins. Working with Oak Ridge National Laboratory and the Cleveland Clinic, IBM computed nine molecular configurations of FLiBe, a molten salt relevant to tritium production in fusion reactors. The work, published on the arXiv preprint server, leans on what IBM calls quantum-centric supercomputing and targets tritium extraction for future fusion plants — a sector still far from commercial viability. In a separate effort, researchers using IBM's 156-qubit Heron processor pulled off an error-mitigated simulation of a Floquet Ising magnet that outperformed classical methods. The collaboration included BlueQubit, Qedma, and Japan's RIKEN, and notably achieved precise results without full error correction — a notoriously expensive process whose absence could open the door to earlier commercial applications.
Washington is starting to pay attention. On Tuesday, Congressman Nick Langworthy introduced the "American Quantum Competitiveness Act," a bill that would make the Commerce Department the lead agency for commercial quantum technology, shield supply chains from Chinese influence, and set a national strategy. The Quantum Industry Coalition — which counts Google and Microsoft alongside IBM — has thrown its weight behind the measure. For a company that helped pioneer the field, such industrial-policy backing could prove decisive in a race that also features processors from Japan and China.
Yet for all the quantum momentum, it's the legacy business that keeps the lights on. IBM continues to expand its enterprise AI partnerships, its software franchise is growing, and generative AI bookings are climbing. The consulting arm, however, is navigating a more cautious spending environment among clients — a reminder that AI demand isn't lifting every division equally.
Should investors sell immediately? Or is it worth buying IBM?
The market's verdict on all this has been mixed at best. The stock traded at 198.42 euros in German markets, roughly 6 percent below its 50-day average of 211.23 euros. It sits 32 percent under its 52-week high of 292.85 euros, though it has recovered 13 percent from its yearly low. In U.S. trading on Tuesday, shares slipped about 1.2 percent to close at 198.92 euros in Germany — a drop that wasn't IBM's fault alone. Renewed U.S. strikes tied to the Iran conflict pushed oil prices higher and sent bond yields to their highest level since January 2025, dragging down the Dow, S&P 500, and Nasdaq alike.
That macro backdrop lands at an awkward moment. IBM's second-quarter results beat the earnings consensus at $2.93 per share but missed on revenue, coming in at $17.16 billion against expectations of $17.46 billion. The question hanging over the stock is whether software and generative AI momentum can close that gap before headwinds — rising rates, expensive oil, and a potentially more hawkish Federal Reserve — compress valuations across the tech sector.
The bulls have plenty of ammunition. Bank of America carries a $330 price target with a buy rating, Goldman Sachs sees $270, JPMorgan $250, and Citigroup $245 — all well above current levels. Their confidence rests partly on IBM's growing role in AI governance, an area where the company is positioning itself alongside partners like Boomi and Ping Identity to help enterprises secure and control AI agents. Palo Alto Networks CEO Nikesh Arora's warnings about inadequate cybersecurity infrastructure have only added urgency to that pitch. The quantum research with RIKEN, Oak Ridge, and the University of Chicago reinforces the sense of technological depth beyond the core business.
The bears aren't silent either. The stock's slide below both its 50-day and 200-day averages points to a damaged medium-term trend, and the revenue miss shows that AI promises don't automatically translate into numbers. Market participants are pricing in roughly a two-thirds chance of a Fed rate hike in September, which would hit high-multiple tech names hardest. Wells Fargo has warned of "broad caution" for September, and JPMorgan's trading desk has turned tactically defensive following recent Fed signals. If clients keep trimming consulting budgets amid economic uncertainty, IBM's weakest division stays weak for longer.
One near-term anchor: the dividend payment of $1.69 per share scheduled for September 10, which at least signals stability. The real catalyst, though, is the next earnings report — the moment when investors will see whether the software engine can finally outrun the consulting drag and the macro clouds gathering overhead.
Ad
IBM Stock: New Analysis - 2 September
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
